StockWatch
·

Alamar Biosciences, Inc. Q1 FY26 Results

ALMRQ1 FY26 Results
Filing
MetricValue ($ M)Q1 FY25
Revenue26.0498.9%
Total Income26.0498.9%
Expenditure38.3877.4%
PBT-20.86172.3%
Net Profit-21.33178.5%
OPM-47.42%17.91pp
NPM-81.91%23.40pp
EPS-1.74155.9%
View full financials

Alamar Biosciences Reports Q1 2026 Revenue of $26.0 Million, Up 99% YoY

08 May 2026 · 8 May, 5:41 pm

Summary

Alamar Biosciences reported a strong first quarter in 2026, with revenue reaching $26.0 million, a 99% increase year-over-year. The growth was driven by increases in both instrument and consumable revenue. Gross margin improved to 56% due to manufacturing efficiencies and higher average selling prices. The company completed its initial public offering in April, raising $197.8 million in net proceeds. Alamar Biosciences intends to provide full-year 2026 revenue guidance in conjunction with its second quarter 2026 earnings release in August 2026.

Key Highlights

  1. 1

    Alamar Biosciences generated $26.0 million in total revenue for the first quarter of 2026, representing a 99% increase compared to the same period in 2025.

  2. 2

    Instrument revenue grew by 78% to $7.4 million in the first quarter of 2026, driven by an increase in instrument placements.

  3. 3

    Consumable revenue increased by 178% to $14.0 million in the first quarter of 2026, primarily due to pull-through from a larger installed base.

  4. 4

    The gross margin for the first quarter of 2026 was 56%, compared to 49% for the corresponding prior-year period.

  5. 5

    Alamar Biosciences launched two new products, NULISAseq™ Neuro 220 Panel and NULISAqpcr™ AD 5-plex Assay, enhancing its position in neurodegenerative disease research.

  6. 6

    The company raised approximately $220 million in gross proceeds from its initial public offering in April 2026.

  7. 7

    Cash, cash equivalents, and restricted cash were $69.5 million as of March 31, 2026.

Management Comments

Y

Yuling Luo

"We began 2026 with a record quarter, nearly doubling revenue year over year as our NULISA platform gained rapid global traction among leading academic research and biopharma customers," said Yuling Luo, PhD, founder, CEO, and chair of Alamar Biosciences. "With our balance sheet significantly strengthened by the proceeds of our recent IPO, we are well-positioned to accelerate adoption of our Precision Proteomics platform and establish a new gold standard in protein detection and analysis."

Informational and educational content only. Not investment advice.